Publications
Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2005. PMID: 16194454
Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene. 2005. PMID: 16007225
Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005. PMID: 16098367
Rubenstein JL, Treseler P, O'Brien JM. Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematology/oncology clinics of North America. 2005. PMID: 16083831
Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC. A mouse model of juvenile hemochromatosis. The Journal of clinical investigation. 2005. PMID: 16075059
Ashworth A. Oh what a tangled web it weaves: BRCA1 and DNA decatenation. Cancer cell. 2005. PMID: 16098462
Yue N, Heron DE, Komanduri K, Huq MS. Prescription dose in permanent (131)Cs seed prostate implants. Medical physics. 2005. PMID: 16193779
Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Current opinion in pharmacology. 2005. PMID: 15955736
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer. 2005. PMID: 15999098
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer. 2005. PMID: 15999098
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer. 2005. PMID: 15999098
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer. 2005. PMID: 15999098
Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005. PMID: 16027440
Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005. PMID: 16027440
Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005. PMID: 16027439
Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005. PMID: 16027439
Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. PMID: 16033836
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network. Anal canal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2005. PMID: 16038641
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network. Colon cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2005. PMID: 16038639
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer Network. Rectal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2005. PMID: 16038640